Try our beta test site
18 studies found for:    lymphoma OR CLL | Ruxolitinib
Show Display Options
Rank Status Study
1 Recruiting Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Incyte Corporation
2 Recruiting Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor/Collaborators: Memorial Sloan Kettering Cancer Center;   Cornell University;   Dana-Farber Cancer Institute
3 Recruiting Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Interventions: Drug: Bortezomib;   Drug: Ruxolitinib
Phase: Phase 1
Sponsor: University of Michigan Cancer Center
4 Active, not recruiting Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor: Samsung Medical Center
5 Completed Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Intervention: Drug: Ruxolitinib
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Sunnybrook Health Sciences Centre;   Novartis
6 Recruiting JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor: University of Cologne
7 Active, not recruiting A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor/Collaborators: The Lymphoma Academic Research Organisation;   Novartis
8 Recruiting Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Interventions: Drug: oral JAK inhibitor INCB18424;   Other: laboratory biomarker analysis;   Other: pharmacological study
Phase: Phase 2
Sponsor/Collaborators: University of Nebraska;   Incyte Corporation
9 Recruiting Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaire
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Incyte Corporation
10 Not yet recruiting Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Interventions: Drug: ruxolitinib;   Drug: ibrutinib
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Sunnybrook Health Sciences Centre;   Novartis
11 Recruiting A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Phase: Phase 2
Sponsor/Collaborators: Incyte Corporation;   Children's Oncology Group
12 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Intervention: Drug: Ruxolitinib
Phase: Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
13 Recruiting Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Interventions: Drug: Ruxolitinib;   Drug: Dasatinib;   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Memorial Sloan Kettering Cancer Center;   Incyte Pharmaceuticals;   Novartis Pharmaceuticals
14 Recruiting Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Interventions: Drug: Ruxolitinib;   Drug: Dasatinib;   Drug: Rituximab;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Solumedrol;   Drug: 6-mercaptopurine;   Drug: Prednisone;   Drug: Leucovorin
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Incyte Corporation
15 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: University Health Network, Toronto;   Novartis
16 Active, not recruiting INCB018424 in Patients With Advanced Hematologic Malignancies
Intervention: Drug: INCB018424
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Incyte Corporation
17 Completed INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Interventions: Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Phase: Phase 1
Sponsor/Collaborators: Children's Oncology Group;   National Cancer Institute (NCI)
18 Recruiting High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Interventions: Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy;   Genetic: Mutation Analysis
Phase:
Sponsor/Collaborators: University of Washington;   National Cancer Institute (NCI)

Study has passed its completion date and status has not been verified in more than two years.